Clinical Trials
49 results for Prostate Cancer
Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer
- Condition: Prostate Adenocarcinoma
- Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
- Study ID: NCT01985828
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
- Condition: Prostate Cancer
- Study ID: NCT01961713
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pyruvate (13C)
- Study ID: NCT02526368
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
- Condition: Prostate Cancer
- Intervention: Other: Active surveillance
- Study ID: NCT00949819
Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost
- Condition: Prostate Cancer
- Study ID: NCT02016248
Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy
- Condition: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
- Study ID: NCT02558946
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- Condition: Prostatic Neoplasms
- Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
- Study ID: NCT02102477
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Study ID: NCT02643511
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study
- Condition: Locally Advanced and Metastatic Prostate Cancer
- Intervention: Procedure: Radical prostatectomy
- Study ID: NCT02971358
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
- Study ID: NCT01492972
Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).
- Condition: Prostatic Neoplasms, Neoplasm Metastasis
- Study ID: NCT02138721
Collection of Blood From Patients With Prostate Cancer
- Condition: Prostatic Neoplasms
- Study ID: NCT00923221
Canary Prostate Active Surveillance Study
- Condition: Prostatic Neoplasms
- Study ID: NCT00756665
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Study ID: NCT00588185
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer
- Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
- Study ID: NCT00050752
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Study ID: NCT00026884
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
- Study ID: NCT00969111
A Randomized Trial of Modifications to Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
- Study ID: NCT01407263
Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition
- Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
- Study ID: NCT01441089
Biospecimen Acquisition From Human Subjects
- Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Study ID: NCT00034216
Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer
- Condition: Prostate Carcinoma
- Study ID: NCT02739659
HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields
- Condition: Prostate Cancer
- Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
- Study ID: NCT02918253
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
- Condition: Post Prostatectomy
- Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03160794
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
- Condition: Prostate Cancer
- Intervention: Other: Standard of Care
- Study ID: NCT03151629
Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial
- Condition: Prostate Cancer
- Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
- Study ID: NCT03482089
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
- Condition: Prostate Cancer, Localized Malignant Neoplasm
- Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Study ID: NCT01766492
A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer
- Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
- Study ID: NCT04253483
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
- Condition: Oligometastatic Hormone Sensitive Prostate Cancer
- Study ID: NCT04115007
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Fol
- Condition: Prostatic Neoplasms
- Study ID: NCT04557059
Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan
- Condition: Metastatic Castration-sensitive Prostate Cancer
- Study ID: NCT04601441
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Condition: Prostatic Neoplasms
- Study ID: NCT04720157
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Study ID: NCT04513717
A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer
- Condition: Biochemically Recurrent Prostate Cancer
- Study ID: NCT05526248
Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04984343
Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
- Condition: Prostate Cancer
- Study ID: NCT05345444
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
- Condition: Prostate Adenocarcinoma
- Study ID: NCT05050084
Drug Use Investigation of Darolutamide in Addition to Standard Androgen Deprivation Therapy (ADT) and Docetaxel in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Study ID: NCT06010914
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04396808
Tolerability of Concurrent EBRT + Lu-PSMA for Node-positive Prostate Cancer (PROQURE-1)
- Condition: Prostatic Neoplasm
- Study ID: NCT05162573
Multiple-Arm Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
- Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT05733351
A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)
- Condition: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
- Study ID: NCT05498272
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Condition: Metastatic Castrate-sensitive Prostate Cancer
- Study ID: NCT05884398
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
- Condition: Prostate Cancer, Prostatic Neoplasms
- Study ID: NCT06056830
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- Condition: Cancer Of Prostate
- Study ID: NCT05361798
Pilot Clinical Trial of Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
- Condition: Prostate Cancer, Cancer of Prostate
- Study ID: NCT04887935
A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance
- Condition: Prostate Adenocarcinoma
- Intervention: Drug: Hyperpolarized Carbon C 13 Pyruvate, Procedure: Magnetic Resonance Spectroscopic Imaging, Procedure: MRI Ultrasound Fusion Guided Biopsy
- Study ID: NCT03933670
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Localized Prostate Cancer
- Condition: Prostate Cancer, Localized Prostate Carcinoma
- Study ID: NCT05851365
A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men With Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT06074510
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- Condition: Prostate Cancer
- Study ID: NCT04995198